Under disease conditions including obesity (insulin resistance) and diabetes, dysregulation of adipokines such as tumor necrosis factor (TN-F)-α, leptin, resistin, and adiponectin contribute to the development of metabolic and cardiovascular disease. Unlike other adipokines, adiponectin has been shown to be a therapeutic target for metabolic syndrome and cardiovascular disease. Circulating levels of adiponectin are markedly reduced in obese, diabetic, hypertensive, and coronary artery disease patients as well as experimental animal models of insulin resistance and diabetes. Recently, the small molecule adiponectin receptors (AdipoRs) agonist was discovered and suggested that the agonist is a novel therapeutic target for the treatment of type 2 diabetes linked to obesity in an experimental mouse model. This review will focus on signaling pathways involved in adiponectin and its receptors and the role of adiponectin in metabolic and cardiovascular disease including insulin resistance, cardiomyopathy, and cardiovascular dysfunction.
INTRODUCTION
Metabolic syndrome including insulin resistance, hypertension, and type 2 diabetes, is more linked to the development of cardiovascular complications such as stroke and cardiac arrest (Arnlov et al., 2010) . Adipose tissue produces a number of bioactive substances known as adipokines including tumor necrosis factor (TN-F)-α, leptin, resistin, and adiponectin (Deng and Scherer, 2010) . Under disease conditions including obesity (insulin resistance) and type 2 diabetes, dysregulation of these adipokines contribute to the development of metabolic and cardiovascular disease (Guzik et al., 2006; Tilg and Moschen, 2006) . Adiponectin is a 30 KDa protein abundantly secreted from adipocytes and circulates at high concentration in the blood (3-30 µg/mL) as three oligomeric complexes (Ouchi et al., 2003a; Tsao et al., 2003) . Unlike other adipokines, adiponectin plays a protective role against the development of metabolic disorder and related atherosclerotic vascular disease Okamoto et al., 2000; Zoccali et al., 2002) . In the rodent models, deletion of adiponectin is associated with the increased inflammatory actions under conditions of stresses such as over-nutrition and ischemic insult Nawrocki et al., 2006; Shibata et al., 2005) . Circulating levels of adiponectin are markedly reduced in obese (Arita et al., 1999) , diabetic (Hotta et al., 2000) , hypertensive (Adamczak et al., 2003) , and coronary artery disease (Kumada et al., 2003; Nakamura et al., 2004) patients as well as experimental animal models of insulin resistance and diabetes Lee et al., 2012) . In addition, a number of clinical observations demonstrated that serum hypoadiponectinemia is associated with impaired endothelial-dependent vasodilation (Ouchi et al., 2003b) , hypertension (Chow et al., 2007) , myocardial infarction (Pischon et al., 2004) , and coronary artery disease (Kiris et al., 2006) . This review will focus on 1) signaling pathways involved in adiponectin and its receptors and 2) the role of adiponectin in metabolic and cardiovascular disease including insulin resistance, cardiomyopathy, and vascular dysfunction.
ADIPONECTIN AND ADIPONECTIN RECEPTORS
Adiponectin secreted from adipose tissue binds to two distinct adiponectin receptors (AdipoR1 and AdipoR2) identified and exerts its anti-diabetic effects through activation of AMP-activated protein kinase (AMPK) and peroxisome proliferator-activated receptor (PPAR)α pathways in liver and skeletal muscles as well as amelioration of vascular dysfunction through activation of endothelial nitric oxide (NO) production and anti-atherogenic effects through inhibition of inflammation in the various vasculature Omae et al., 2013; Yamauchi et al., 2003; Yamauchi et al., 2002) . Adiponectin consists of 247 amino acids and circulates in the bloodstream as three different oligomeric complexes including trimer (3), hexamer (6) and high molecular weight multimer (12-18) (Magkos and Sidossis, 2007) . Adiponectin receptors contain seven transmembrane domains, but they are distinct from G-protein-coupled-receptors (GPCR) structurally and functionally (Wess, 1997; Yamauchi et al., 2003) . Replenishment of adiponectin has been shown to ameliorate insulin resistance, glucose intolerance, and vascular function in animal models (Cao et al., 2009; Yamauchi et al., 2002; Yamauchi et al., 2001) , while hypoglycemic effects of adiponectin in liver was abrogated in the double knockout of AdipoR1 and 2 in the mouse model (Yamauchi et al., 2007) . The beneficial effect of adiponectin in insulin-sensitive organs including skeletal muscle and liver appears to be mediated by an increase in glucose utilization and fatty-acid oxidation via activation of AMPK and PPARα (Kadowaki and Yamauchi, 2005) . AdipoR1 is abundantly expressed and activates AMPK in skeletal muscle, while in liver, AdipoR2 is predominantly expressed and regulated glucose and lipid metabolism, inflammation, and oxidative stress through PPARα (Cao et al., 2009; Kadowaki and Yamauchi, 2005; Savage et al., 2005; Yamauchi et al., 2001 ). In addition, adiponectin played a protective role in the pathogenesis of vascular diseases by promoting NO production as well as inhibiting inflammation and oxidative stress. For example, deficiency of adiponectin showed impairment of endothelium-dependent vasodilation (Ouchi et al., 2003b; Shimabukuro et al., 2003) . Recently, Okada-Iwabu et al. (2013) have implicated that orally active AdipoR agonists (AdipoRON) showed similar effects to adiponectin via AdipoR1 and 2 in the both liver and skeletal muscle of experimental diabetic mouse model, suggesting that adiponectin receptors could be a promising therapeutic target for the treatment of type 2 diabetes.
ADIPONECTIN AND CHRONIC DISEASE

Obesity, insulin resistance, and diabetes
Insulin resistance linked to obesity is a major risk factor for type 2 diabetes and cardiovascular disease. The skeletal muscle and liver, which are the principal storage for glucose and fatty acids, are responsible for energy homeostasis (Savage et al., 2005) . Obesity and/or high fat diet feeding increased free fatty acids (FFA) in circulation and result in insulin resistance (Dresner et al., 1999) . Elevated FFA reduced insulin-stimulated glucose disposal and resulted in the reduction of glycogen synthesis in both skeletal muscle and liver (Boden and Shulman, 2002) . It is well established that glycogen synthesis was reduced in diabetic subjects compare to normal individuals (Shulman et al., 1990) . In both liver and skeletal muscle, adiponectin reduced triglyceride content and improved insulin signaling by increasing gene expression involved in fatty acid oxidation (Yamauchi et al., 2001) . Previous studies have shown that adiponectin increased insulin sensitivity, resulting in decreases in both serum glucose and hepatic glucose production by inhibiting expression of hepatic gluconeogenic enzymes and the rate of endogenous glucose production Combs et al., 2001) .
Cardiomyopathy
In addition to beneficial effect on insulin-sensitive organs, some experimental animal studies implicate that the overexpression of adiponectin protects heart from ischemia-reperfusion injury, cardiomyopathy, and cardiac dysfunction, whereas its deficiency exacerbates cardiac damage owing to stress response Shibata et al., 2005; Tao et al., (2007) . Shibata et al showed that adiponectin deficiency increased myocardial infarction (30 min ischemia-24 h reperfusion), apoptosis, and inflammatory cytokine (TNF-α), while adiponectin supplementation by injection of adenoviral vectors expressing adiponectin diminished infarct size, cardiac apoptosis, and TNF-α production in part, through activation of both AMPK-and COX2-dependent signaling pathways (Shibata et al., 2005) . In another study by Tao et al. (2007) , they also showed that adiponectin knock-out mice enhanced myocardial infarct size (30 min ischemia-3 h or 24 h reperfusion) and apoptosis, while acute administration of globular adiponectin attenuated myocardial ischemia-reperfusion injury, in part, through anti-oxidant (decreased gp91 phox and superoxide production) and anti-nitrative mechanisms (decreased iNOS and peroxynitrite). Taken together, these studies suggest that adiponectin play an important role in protecting ischemia and reperfusion injury by inhibiting apopto-sis, inflammation, and oxidative/nitrative stress.
Vascular dysfunction and atherosclerosis
Previous studies in human demonstrated that hypoadiponectinemia is associated with vascular dysfunction and a good predictor of endothelial function of coronary artery (Okui et al., 2008; Shimabukuro et al., 2003) . Consistent with clinical studies, deficiency of adiponectin in mice impaired endothelial-dependent vasorelaxation Lee et al., 2012; Ouchi et al., 2003b) . On the other hand, the overexpression of adiponectin ameliorated vascular dysfunction induced by metabolic abnormalities in both animal model and human subject (Lee et al., 2012; Shimabukuro et al., 2003) . Some studies also implicated the possible action of adiponectin in the development of atherosclerotic plaques, which occurs infiltration of monocyte to the vasculature where they differentiate into macrophage (Chinetti et al., 2004; Zhu et al., 2008) . Interestingly, it was reported that replenishment of adiponectin reduced atherosclerotic lesion in apolipoprotein E (apoE) knock-out mice . Another pathway in which adiponectin has protective effect on vascular system through anti-oxidant activity is by augmenting the production of endothelial NO as well as inhibiting oxidative stress. It is reported that adiponectin has the ability to increase NO production by eNOS phosphorylation and decreased NO inactivation by inhibiting superoxide production in the vasculature and endothelial cells (Cao et al., 2009; Chen et al., 2003) . Even though a number of studies have shown that reduced adiponectin levels were observed in metabolic and cardiovascular disease, it is not clear whether these diseases cause reduction of AdipoRs in blood vessels and vascular cells including endothelial and smooth muscle cells. A summary of studies examining the expression of AdipoRs in vasculatures and vascular cells is provided in Table 1 . Considering the literature, both AdipoR1 and 2 are expressed in endothelial and vascular smooth muscle cells of various vascular bed including aorta, coronary arterioles, and retinal artery. A few studies have demonstrated that the experimental mouse model of type 2 diabetes decreased protein expression of AdipoR2 without alteration of AdipoR1 in aorta and coronary arterioles Zhang et al., 2010) . One promising therapeutic strategy to combat diabetes and vascular disease may be to up-regulate AdipoRs or activate the receptors with agonists to increase sensitivity of adiponectin. In this perspective, the small molecule AdipoRs agonist proposed by Okada-Iwabu et al. (2013) would be interesting topic to determine whether the agonist could ameliorate vascular dysfunction in cerebral and coronary arteries.
CONCLUSIONS
Adiponectin is an adipose tissue-derived protein that appears to play an important role in preventing and ameliorating insulin resistance, diabetes, and related cardiovascular dysfunction. Diminished level of adiponectin was observed in obese, diabetic, and coronary artery disease patients and has been reported to be a useful predictor of diabetes and cardiovascular disease in human. To date, two adiponectin receptors including AdipoR1 and 2 were identified and it is known that the receptors are required for beneficial action of adiponectin. The anti-diabetic drugs such as thiazolidinediones (TZDs) increase adiponectin in both animals and human (Hiuge-Shimizu et al., 2011; Tao et al., 2010) . Recently, the small molecule AdipoRs agonist, AdipoRON was discovered by Okada-Iwabu et al. (2013) and they suggested that the agonist is a novel therapeutic target for the treatment of type 2 diabetes lined to obesity in an experimental diabetic mouse model. Considering previous studies, a number of studies have shown that administration of adiponectin has beneficial effects on endothelial-dependent vasodilation and inhibition of atherosclerosis via NO-mediated signaling pathway. In this case, it is very tempting to speculate that the AdipoRs agonist could be a novel therapeutic target for treatment of vascular dysfunction. Further studies will facilitate a better understanding of the mechanism underlying agonists for AdipoRs in the development of therapeutic intervention in vascular disease.
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